MyoGene Bio is Granted Orphan Drug Designation and Rare Pediatric Disease Designation

November 19, 2024

MyoGene Bio has announced that MyoDys45-55, our gene editing therapy for Duchenne, was recently granted Orphan Drug Designation and Rare Pediatric Disease designation by FDA. These designations offer incentives to support the approval of MyoDys45-55 and advance it to patients as quickly as possible.

 Read more here:  https://www.einpresswire.com/article/760743569/myogene-granted-orphan-drug-designation-and-rare-pediatric-disease-designation-for-duchenne-muscular-dystrophy-program